Product Program year 2025 Source: CMS Open Payments

Jelmyto

Drug Urothelial Cancer

NDC 72493-103-03

Open in the dashboard

General payments

$2,448,357

28,592 payments

Research payments

$305,365

98 payments

Through program year 2025, $2,448,357 in general payments and $305,365 in research payments were reported against Jelmyto (Urothelial Cancer).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

10 rows
Year Kind Amount Payments
2025 General $366,784 5,302
2025 Research $76,958 13
2024 General $662,465 7,689
2024 Research $96,448 7
2023 General $421,259 6,414
2023 Research $103,594 16
2022 General $361,889 5,248
2021 General $581,852 3,370
2020 General $54,108 569
2020 Research $28,366 62

Breakdown

Who paid General payments · program years 2020–2025
  1. Urogen Pharma, Inc. $2,448,357 28,592 payments
Top recipients General payments · program year 2025
  1. Katie Murray Urology · New York, NY $54,017 15% · 40 payments
  2. Marc Bjurlin Urology · Kinston, NC $38,222 10% · 25 payments
  3. Sandip Prasad Urology · Charleston, SC $18,599 5% · 15 payments
  4. Vignesh Packiam Urology · Iowa City, IA $12,345 3% · 12 payments
  5. Armine Smith Urology · Washington, DC $11,370 3% · 7 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Urology $279,275 83% · 1,835 practitioners
  2. Physician Assistant $15,183 5% · 335 practitioners
  3. Nurse Practitioner, Family Nurse Practitioner $12,736 4% · 253 practitioners
  4. Nurse Practitioner $7,243 2% · 143 practitioners
  5. Surgery $6,952 2% · 19 practitioners

The top 5 of 51 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. New York $72,072 20% · 193 recipients
  2. North Carolina $46,286 13% · 94 recipients
  3. California $27,716 8% · 178 recipients
  4. Texas $20,239 6% · 234 recipients
  5. South Carolina $20,140 5% · 43 recipients

The top 5 of 51 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

Given in the clinic

Part B · billing code
Medicare Part B billing codes matched to JELMYTO
Billing code Providers Services Paid by Medicare
Mitomycin pyelocalyceal instillation, 1 mg J9281 1 1,400 $17,562

Drugs given by a clinician are billed to Medicare Part B, not Part D. The product is tied to a billing code through the NDC on CMS's crosswalk, which was published for a later quarter than the payments, so a code that changed in between can be missed. Providers with fewer than 11 patients for the code are not published. Medicare's payment here is what it paid for the services, to the billing practice.

28,592 general · 98 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record